Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $473M; returns 1 day -6.8%, 1 week -3.5%, 1 year -46.9%.

REGENXBIO Inc. (RGNX) is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary AAV (adeno-associated virus) vector platform, NAV Technology. The company generates revenue primarily through licensing agreements and collaborations with larger pharma partners, who leverage REGENXBIO's gene delivery technology for their own programs.

Groups RGNX belongs to

• Biotechnology
• Gene Therapy
• Clinical Stage Biotech
• Healthcare
• Life Sciences
• Clinical Stage
• Rare Diseases
• Ophthalmology
• Duchenne Muscular Dystrophy
• Biopharmaceutical
• Royalty Streams
• Precision Medicine

RGNX financial model: income statement, cash flow and balance sheet